Drugs · Entity Annotation Prototype (beta)

4articles mentioning drugs

6drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: talimogene laherparepvec ×

talimogene laherparepvec

This drug is selected. Its supporting articles are shown below.

Talimogene laherparepvec4

Articles mentioning talimogene laherparepvec

4 articles · page 1 of 1

Bladder-sparing strategies for non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure: a systematic review

bmjonc · full text · 2026-02-01 · 2 matching annotations

80.5%

valrubicin pembrolizumab nadofaragene firadenovec Durvalumab erdafitinib

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

895 The lack of abscopal effects with oncolytic virus immunotherapy is due to a dominant anti-viral – rather than anti-cancer – T cell response

jitc · abstract · 2025-11-04 · 2 matching annotations

95.9%

Talimogene laherparepvec talimogene laherparapvec pembrolizumab B16F10 melanoma Massachusetts General Hospital MGH

…Y, Yao B, Li A, Doleman S, VanderWalde A, Gansert J, Coffin RS. Talimogene laherparepvec improves durable respose rate in patients with advanced melanom…

Real-world outcomes of talimogene laherparepvec as salvage therapy for advanced melanoma

jitc · abstract · 2025-12-25 · 1 matching annotations

92.0%

Talimogene laherparepvec T-VEC metastatic melanoma unresectable and metastatic melanoma

…Background Talimogene laherparepvec (T-VEC) is an oncolytic herpes simplex virus therapy approved f…

Addition of oncolytic virotherapy to clinical isolated limb perfusion for melanoma and sarcoma activates antitumor immunity

jitc · abstract · 2025-09-26 · 1 matching annotations

82.8%

melphalan tumor necrosis factor-alpha talimogene laherparepvec melanoma sarcoma

…ic herpes simplex virus, talimogene laherparepvec (T-VEC), with melphalan and tumor necrosis factor-alpha delivered by ILP, in patients w…